NR 566 Final Exam: Questions & Answers (Update)
Advanced Pharmacology - Care of the Family | 2026/2027
Edition | 150 Verified Questions
NR 566 Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 566 Advanced Pharmacology - Care of the Family
contains 150 verified questions and answers designed to help students master pharmacotherapeutic
concepts for family care. Covering key topics such as pharmacokinetics, drug classifications, and
evidence-based prescribing for common acute and chronic conditions, this resource reflects the latest
2026/2027 guidelines. Each question includes detailed rationales to reinforce learning and ensure exam
readiness.
Key Features:
150 verified questions with correct answers and rationales
Updated for 2026/2027 academic year and latest clinical guidelines
Covers pharmacokinetics, pharmacodynamics, and drug interactions
Focus on family-centered prescribing across the lifespan
Includes high-yield topics for common acute and chronic conditions
Designed to support A+ exam performance
Updates for 2026:
- Revised to align with 2026/2027 NR 566 curriculum updates
- Incorporated latest FDA approvals and black box warnings
- Updated rationales to reflect current evidence-based practice
- Added new questions on emerging pharmacotherapies
- Enhanced distractor explanations for improved critical thinking
Abstract:
This document provides a rigorous review of advanced pharmacology principles essential for family care, as tested
in the NR 566 final exam. The 150 questions are organized by content area, covering drug classes, mechanisms of
action, adverse effects, and therapeutic monitoring. Emphasis is placed on safe prescribing for special populations
including pediatrics, geriatrics, and pregnant or lactating patients. Each question is accompanied by a detailed
rationale explaining why the correct answer is optimal and why distractors are incorrect, fostering deep
understanding rather than rote memorization. Updated for the 2026/2027 academic year, this resource
incorporates the most recent clinical practice guidelines and pharmacological advancements. It is an
indispensable tool for students aiming to achieve a top score on the final exam.
Keywords:
NR 566, Advanced Pharmacology, Family Care, Exam Prep, 150 Questions, 2026/2027, Pharmacotherapeutics,
Chamberlain University
Answer Format:
Each question is presented with four answer options, followed by the correct answer and a detailed rationale.
Rationales explain the pharmacological basis for the correct choice and clarify why each distractor is incorrect,
often referencing specific drug mechanisms, side effects, or clinical guidelines.
Compliance Checklist:
Updated for 2026/2027 academic year
Page 1
, Aligned with NR 566 course objectives
Includes rationales for all answers
Covers lifespan considerations in prescribing
Reflects current evidence-based practice
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-25 Absorption, distribution, metabolism, 17%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic and Cardiovascular 26-50 Adrenergic agonists/antagonists, 17%
Pharmacology cholinergics, antihypertensives,
antiarrhythmics, heart failure drugs
Central Nervous System 51-75 Antidepressants, antipsychotics, anxiolytics, 17%
Pharmacology stimulants, analgesics, anticonvulsants
Endocrine and Metabolic 76-100 Diabetes agents, thyroid drugs, 17%
Pharmacology corticosteroids, osteoporosis therapies,
lipid-lowering agents
Infectious Disease and 101-125 Antibiotics, antivirals, antifungals, vaccines, 17%
Immunology immunomodulators
Special Populations and 126-150 Pediatric dosing, geriatric considerations, 15%
Toxicology pregnancy/lactation, drug interactions,
overdose management
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is being initiated
on an SGLT2 inhibitor. Which of the following considerations is most critical regarding this therapy?
A. SGLT2 inhibitors are contraindicated in all patients with eGFR <45 mL/min/1.73 m².
B. Dapagliflozin can be used with dose adjustment for renoprotective benefits even at low eGFR.
C. Empagliflozin is preferred due to its cardiovascular benefit, but its efficacy for glycemic control diminishes
at eGFR <45 mL/min/1.73 m².
D. SGLT2 inhibitors increase the risk of acute kidney injury and should be avoided in CKD.
Correct Answer: C. Empagliflozin is preferred due to its cardiovascular benefit, but its efficacy for glycemic
control diminishes at eGFR <45 mL/min/1.73 m².
Rationale: Empagliflozin retains cardiovascular and renal benefits even when glycemic efficacy wanes at lower
eGFR. Current guidelines support use for heart failure and CKD progression prevention. Option A is outdated;
some SGLT2 inhibitors are not contraindicated but efficacy reduces. Option B incorrectly states dapagliflozin is
used without restriction; it requires eGFR >25 to initiate. Option D overstates risk; SGLT2 inhibitors are
renoprotective when used appropriately.
Why Wrong:
A - This is outdated; SGLT2 inhibitors are not absolutely contraindicated at eGFR <45 but have reduced
glucose-lowering efficacy.
B - Dapagliflozin initiation requires eGFR 25 mL/min, not unrestricted use at low eGFR.
D - SGLT2 inhibitors are associated with renoprotective effects, not increased AKI risk, when used in
appropriate populations.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45; ADA Standards of Medical Care
in Diabetes-2024.
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 without bleeding. Which of the
following management strategies is most appropriate?
A. Administer 5 mg of oral vitamin K and hold warfarin for 1-2 days.
B. Administer 10 mg of intravenous vitamin K and fresh frozen plasma.
C. Hold warfarin and administer 1-2.5 mg of oral vitamin K.
D. Administer 2.5 mg of oral vitamin K and resume warfarin at a lower dose.
Correct Answer: C. Hold warfarin and administer 1-2.5 mg of oral vitamin K.
Rationale: For INR between 4.5 and 10 without bleeding, guidelines recommend holding warfarin and giving
low-dose oral vitamin K (1-2.5 mg) to expedite return to therapeutic range. Option A uses too high a dose (5 mg).
Option B is for major bleeding. Option D incorrectly suggests resuming warfarin immediately with a lower dose
without first managing the supratherapeutic INR.
Why Wrong:
A - 5 mg oral vitamin K is excessive for non-bleeding supratherapeutic INR; may cause overcorrection.
B - IV vitamin K and FFP are reserved for major bleeding, not INR 5.2 without bleeding.
D - Resuming warfarin immediately is premature; the elevated INR must be managed first.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; CHEST Guideline 2021.
Q3. Which of the following best explains the rationale for using a beta-blocker (e.g., metoprolol) in a patient
with heart failure with reduced ejection fraction (HFrEF) who has compensated volume status?
A. Beta-blockers improve cardiac output by increasing heart rate and contractility.
B. Beta-blockers reduce the deleterious effects of chronic sympathetic activation, leading to reverse
remodeling.
C. Beta-blockers are primarily used to control hypertension in HFrEF patients.
D. Beta-blockers prevent arrhythmias but do not affect mortality in HFrEF.
Correct Answer: B. Beta-blockers reduce the deleterious effects of chronic sympathetic activation, leading to
reverse remodeling.
Page 3
, Rationale: Chronic sympathetic activation in HFrEF causes adverse remodeling and progression. Beta-blockers antagonize
this, improving left ventricular function and reducing mortality. Option A is incorrect because beta-blockers lower heart rate
and contractility, but improve efficiency. Option C is secondary; the main benefit is mortality reduction. Option D is false;
beta-blockers reduce mortality in HFrEF.
Why Wrong:
A - Beta-blockers actually decrease heart rate and contractility, not increase them.
C - Blood pressure control is not the primary mortality benefit in HFrEF.
D - Beta-blockers are proven to reduce mortality in HFrEF, not just prevent arrhythmias.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48; ACC/AHA/HFSA Guideline for the
Management of Heart Failure (2022).
Q4. A patient with major depressive disorder has been on fluoxetine 40 mg daily for 8 weeks with minimal
improvement. The provider considers augmentation with a second agent. Which of the following
combinations is most appropriate based on current evidence?
A. Add aripiprazole 2 mg daily.
B. Add bupropion 150 mg twice daily.
C. Switch to venlafaxine 75 mg daily.
D. Add lithium 300 mg three times daily.
Correct Answer: A. Add aripiprazole 2 mg daily.
Rationale: Aripiprazole is FDA-approved as augmentation for major depressive disorder and is supported by
evidence. Option B (bupropion augmentation) is also used but has less robust evidence and may increase anxiety.
Option C is a switch, not augmentation. Option D (lithium) is effective but less commonly used as first-line due to
monitoring requirements and side effects.
Why Wrong:
B - Bupropion augmentation is a strategy but not as well-supported as aripiprazole and can exacerbate
anxiety.
C - Switching is a different strategy than augmentation; also, venlafaxine may not be more effective.
D - Lithium augmentation is effective but reserved for refractory cases due to monitoring burden.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29; APA Practice Guideline for the
Treatment of Major Depressive Disorder (2023).
Q5. A patient with asthma is prescribed a long-acting beta-agonist (LABA) in combination with an inhaled
corticosteroid (ICS). Which of the following best describes the rationale for using a LABA/ICS combination
rather than a LABA alone?
A. LABA monotherapy increases the risk of asthma-related death due to unopposed beta-2 receptor
downregulation.
B. ICS potentiates the bronchodilator effect of LABA by increasing beta-2 receptor sensitivity.
C. Combination therapy allows for lower doses of both agents, reducing side effects.
D. LABA monotherapy is not recommended because it does not improve lung function.
Correct Answer: A. LABA monotherapy increases the risk of asthma-related death due to unopposed beta-2
receptor downregulation.
Rationale: LABA monotherapy without ICS is associated with increased risk of severe exacerbations and
asthma-related death. The ICS component provides anti-inflammatory control, reducing this risk. Option B is not
the primary rationale; ICS does not directly potentiate LABA. Option C is not always true; combination therapy
may use moderate doses. Option D is incorrect; LABA alone does improve lung function but at the cost of increased
risk.
Why Wrong:
B - ICS primarily reduces airway inflammation, not directly potentiates beta-2 sensitivity.
C - Combination therapy does not necessarily allow lower doses; it is about safety and efficacy.
Page 4
Advanced Pharmacology - Care of the Family | 2026/2027
Edition | 150 Verified Questions
NR 566 Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 566 Advanced Pharmacology - Care of the Family
contains 150 verified questions and answers designed to help students master pharmacotherapeutic
concepts for family care. Covering key topics such as pharmacokinetics, drug classifications, and
evidence-based prescribing for common acute and chronic conditions, this resource reflects the latest
2026/2027 guidelines. Each question includes detailed rationales to reinforce learning and ensure exam
readiness.
Key Features:
150 verified questions with correct answers and rationales
Updated for 2026/2027 academic year and latest clinical guidelines
Covers pharmacokinetics, pharmacodynamics, and drug interactions
Focus on family-centered prescribing across the lifespan
Includes high-yield topics for common acute and chronic conditions
Designed to support A+ exam performance
Updates for 2026:
- Revised to align with 2026/2027 NR 566 curriculum updates
- Incorporated latest FDA approvals and black box warnings
- Updated rationales to reflect current evidence-based practice
- Added new questions on emerging pharmacotherapies
- Enhanced distractor explanations for improved critical thinking
Abstract:
This document provides a rigorous review of advanced pharmacology principles essential for family care, as tested
in the NR 566 final exam. The 150 questions are organized by content area, covering drug classes, mechanisms of
action, adverse effects, and therapeutic monitoring. Emphasis is placed on safe prescribing for special populations
including pediatrics, geriatrics, and pregnant or lactating patients. Each question is accompanied by a detailed
rationale explaining why the correct answer is optimal and why distractors are incorrect, fostering deep
understanding rather than rote memorization. Updated for the 2026/2027 academic year, this resource
incorporates the most recent clinical practice guidelines and pharmacological advancements. It is an
indispensable tool for students aiming to achieve a top score on the final exam.
Keywords:
NR 566, Advanced Pharmacology, Family Care, Exam Prep, 150 Questions, 2026/2027, Pharmacotherapeutics,
Chamberlain University
Answer Format:
Each question is presented with four answer options, followed by the correct answer and a detailed rationale.
Rationales explain the pharmacological basis for the correct choice and clarify why each distractor is incorrect,
often referencing specific drug mechanisms, side effects, or clinical guidelines.
Compliance Checklist:
Updated for 2026/2027 academic year
Page 1
, Aligned with NR 566 course objectives
Includes rationales for all answers
Covers lifespan considerations in prescribing
Reflects current evidence-based practice
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-25 Absorption, distribution, metabolism, 17%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic and Cardiovascular 26-50 Adrenergic agonists/antagonists, 17%
Pharmacology cholinergics, antihypertensives,
antiarrhythmics, heart failure drugs
Central Nervous System 51-75 Antidepressants, antipsychotics, anxiolytics, 17%
Pharmacology stimulants, analgesics, anticonvulsants
Endocrine and Metabolic 76-100 Diabetes agents, thyroid drugs, 17%
Pharmacology corticosteroids, osteoporosis therapies,
lipid-lowering agents
Infectious Disease and 101-125 Antibiotics, antivirals, antifungals, vaccines, 17%
Immunology immunomodulators
Special Populations and 126-150 Pediatric dosing, geriatric considerations, 15%
Toxicology pregnancy/lactation, drug interactions,
overdose management
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) is being initiated
on an SGLT2 inhibitor. Which of the following considerations is most critical regarding this therapy?
A. SGLT2 inhibitors are contraindicated in all patients with eGFR <45 mL/min/1.73 m².
B. Dapagliflozin can be used with dose adjustment for renoprotective benefits even at low eGFR.
C. Empagliflozin is preferred due to its cardiovascular benefit, but its efficacy for glycemic control diminishes
at eGFR <45 mL/min/1.73 m².
D. SGLT2 inhibitors increase the risk of acute kidney injury and should be avoided in CKD.
Correct Answer: C. Empagliflozin is preferred due to its cardiovascular benefit, but its efficacy for glycemic
control diminishes at eGFR <45 mL/min/1.73 m².
Rationale: Empagliflozin retains cardiovascular and renal benefits even when glycemic efficacy wanes at lower
eGFR. Current guidelines support use for heart failure and CKD progression prevention. Option A is outdated;
some SGLT2 inhibitors are not contraindicated but efficacy reduces. Option B incorrectly states dapagliflozin is
used without restriction; it requires eGFR >25 to initiate. Option D overstates risk; SGLT2 inhibitors are
renoprotective when used appropriately.
Why Wrong:
A - This is outdated; SGLT2 inhibitors are not absolutely contraindicated at eGFR <45 but have reduced
glucose-lowering efficacy.
B - Dapagliflozin initiation requires eGFR 25 mL/min, not unrestricted use at low eGFR.
D - SGLT2 inhibitors are associated with renoprotective effects, not increased AKI risk, when used in
appropriate populations.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45; ADA Standards of Medical Care
in Diabetes-2024.
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 without bleeding. Which of the
following management strategies is most appropriate?
A. Administer 5 mg of oral vitamin K and hold warfarin for 1-2 days.
B. Administer 10 mg of intravenous vitamin K and fresh frozen plasma.
C. Hold warfarin and administer 1-2.5 mg of oral vitamin K.
D. Administer 2.5 mg of oral vitamin K and resume warfarin at a lower dose.
Correct Answer: C. Hold warfarin and administer 1-2.5 mg of oral vitamin K.
Rationale: For INR between 4.5 and 10 without bleeding, guidelines recommend holding warfarin and giving
low-dose oral vitamin K (1-2.5 mg) to expedite return to therapeutic range. Option A uses too high a dose (5 mg).
Option B is for major bleeding. Option D incorrectly suggests resuming warfarin immediately with a lower dose
without first managing the supratherapeutic INR.
Why Wrong:
A - 5 mg oral vitamin K is excessive for non-bleeding supratherapeutic INR; may cause overcorrection.
B - IV vitamin K and FFP are reserved for major bleeding, not INR 5.2 without bleeding.
D - Resuming warfarin immediately is premature; the elevated INR must be managed first.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; CHEST Guideline 2021.
Q3. Which of the following best explains the rationale for using a beta-blocker (e.g., metoprolol) in a patient
with heart failure with reduced ejection fraction (HFrEF) who has compensated volume status?
A. Beta-blockers improve cardiac output by increasing heart rate and contractility.
B. Beta-blockers reduce the deleterious effects of chronic sympathetic activation, leading to reverse
remodeling.
C. Beta-blockers are primarily used to control hypertension in HFrEF patients.
D. Beta-blockers prevent arrhythmias but do not affect mortality in HFrEF.
Correct Answer: B. Beta-blockers reduce the deleterious effects of chronic sympathetic activation, leading to
reverse remodeling.
Page 3
, Rationale: Chronic sympathetic activation in HFrEF causes adverse remodeling and progression. Beta-blockers antagonize
this, improving left ventricular function and reducing mortality. Option A is incorrect because beta-blockers lower heart rate
and contractility, but improve efficiency. Option C is secondary; the main benefit is mortality reduction. Option D is false;
beta-blockers reduce mortality in HFrEF.
Why Wrong:
A - Beta-blockers actually decrease heart rate and contractility, not increase them.
C - Blood pressure control is not the primary mortality benefit in HFrEF.
D - Beta-blockers are proven to reduce mortality in HFrEF, not just prevent arrhythmias.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48; ACC/AHA/HFSA Guideline for the
Management of Heart Failure (2022).
Q4. A patient with major depressive disorder has been on fluoxetine 40 mg daily for 8 weeks with minimal
improvement. The provider considers augmentation with a second agent. Which of the following
combinations is most appropriate based on current evidence?
A. Add aripiprazole 2 mg daily.
B. Add bupropion 150 mg twice daily.
C. Switch to venlafaxine 75 mg daily.
D. Add lithium 300 mg three times daily.
Correct Answer: A. Add aripiprazole 2 mg daily.
Rationale: Aripiprazole is FDA-approved as augmentation for major depressive disorder and is supported by
evidence. Option B (bupropion augmentation) is also used but has less robust evidence and may increase anxiety.
Option C is a switch, not augmentation. Option D (lithium) is effective but less commonly used as first-line due to
monitoring requirements and side effects.
Why Wrong:
B - Bupropion augmentation is a strategy but not as well-supported as aripiprazole and can exacerbate
anxiety.
C - Switching is a different strategy than augmentation; also, venlafaxine may not be more effective.
D - Lithium augmentation is effective but reserved for refractory cases due to monitoring burden.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29; APA Practice Guideline for the
Treatment of Major Depressive Disorder (2023).
Q5. A patient with asthma is prescribed a long-acting beta-agonist (LABA) in combination with an inhaled
corticosteroid (ICS). Which of the following best describes the rationale for using a LABA/ICS combination
rather than a LABA alone?
A. LABA monotherapy increases the risk of asthma-related death due to unopposed beta-2 receptor
downregulation.
B. ICS potentiates the bronchodilator effect of LABA by increasing beta-2 receptor sensitivity.
C. Combination therapy allows for lower doses of both agents, reducing side effects.
D. LABA monotherapy is not recommended because it does not improve lung function.
Correct Answer: A. LABA monotherapy increases the risk of asthma-related death due to unopposed beta-2
receptor downregulation.
Rationale: LABA monotherapy without ICS is associated with increased risk of severe exacerbations and
asthma-related death. The ICS component provides anti-inflammatory control, reducing this risk. Option B is not
the primary rationale; ICS does not directly potentiate LABA. Option C is not always true; combination therapy
may use moderate doses. Option D is incorrect; LABA alone does improve lung function but at the cost of increased
risk.
Why Wrong:
B - ICS primarily reduces airway inflammation, not directly potentiates beta-2 sensitivity.
C - Combination therapy does not necessarily allow lower doses; it is about safety and efficacy.
Page 4
